Chronic kidney disease - different role for HDL?

Area of Science:

• Nephrology
• Cardiology
• Lipidology

Background:

• Chronic kidney disease (CKD) is a significant risk factor for cardiovascular mortality, linked to accelerated atherosclerosis.
• Traditional risk factors do not fully explain the elevated cardiovascular risk in CKD patients.
• Renal dysfunction causes significant disturbances in lipoprotein metabolism, leading to dysfunctional high-density lipoprotein (HDL).

Purpose of the Study:

• To investigate the alterations in HDL metabolism and function in patients with chronic kidney disease.
• To understand how these HDL changes contribute to the increased cardiovascular risk in CKD.

Main Methods:

• Analysis of plasma HDL cholesterol levels.
• Assessment of HDL's ability to bind to ABCA1.
• Evaluation of lecithin cholesterol ester transfer protein activity.
• Examination of HDL's vasoprotective, antioxidative, and anti-inflammatory properties.

Main Results:

• CKD patients exhibit lower plasma HDL cholesterol levels.
• Reduced HDL binding to ABCA1 and decreased lecithin cholesterol ester transfer protein activity were observed.
• HDL in CKD patients loses its protective functions, becoming pro-inflammatory and promoting endothelial dysfunction.
• These molecular and functional HDL alterations persist even in renal transplant recipients.

Conclusions:

• Dysfunctional HDL, characterized by altered molecular and functional properties, significantly contributes to cardiovascular risk in CKD.
• The loss of HDL's protective effects and its pro-oxidative/pro-inflammatory nature exacerbate endothelial dysfunction in CKD.
• Therapeutic strategies targeting HDL function may be crucial for managing cardiovascular complications in CKD patients.